Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Shanghai Junshi Biosciences (1877 HK)
Watchlist
224
Analysis
Health Care
•
China
Shanghai Junshi Biosciences Co., Ltd. operates as a biopharmaceutical company. The Company develops and sells small molecule drugs, antibody drug conjugates, and other products. Shanghai Junshi Biosciences markets its products worldwide.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Shanghai Henlius Biotech
•
23 Dec 2024 12:51
Henlius (2696 HK): Circ Out. 22nd Jan H-Class Meeting
Currently at a 2.9% gross spread with expected payment around the third week of Feb. I'd pay up to HK$24.10/share for a 15% annualised spread.
David Blennerhassett
Follow
72 Views
Share
bullish
•
Ping An Healthcare and Technology
•
22 Dec 2024 09:24
China Healthcare Weekly (Dec.22) - Zai Lab, Junshi, How to Choose PA Good Doctor's Special Dividend?
Increasing revenue without increasing profits is a big denial of Zai Lab's business model. Junshi will rebound with strict cost control.There's...
Xinyao (Criss) Wang
Follow
253 Views
Share
bearish
•
Shanghai Junshi Biosciences
•
07 Jul 2024 09:19
China Healthcare Weekly (July.7) - MNCs' Next Move In Licensing Deals, Topchoice, Junshi's Trouble
Investors should wait to see MNCs' next move before deciding on licensing deals. Topchoice's growth is positive but unit price per customer may...
Xinyao (Criss) Wang
Follow
418 Views
Share
bearish
•
Shanghai Junshi Biosciences
•
13 Apr 2023 09:12
[Junshi Biosciences (1877 HK) TP Change]: Medium to near Term Outlook Is Still Cloudy at Best
We continue to view JUNSHI’s Phase III pipeline, consisting of Senaparib (JS109/IMP4297)(PARP), Ongericimab (JS002)(PCSK9), Bevacizumab...
Blue Lotus Research Institute
Follow
351 Views
Share
bullish
•
Innovent Biologics Inc
•
04 Apr 2022 07:57
Innovent Biologics Inc (1801.HK) - Capable of Surviving “this Winter”
After continuous pullback, investors may lose interest in Innovent. However, it still has investment value based on pipeline, resources, R&D and...
Xinyao (Criss) Wang
Follow
308 Views
Share
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.44.3
x